{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:48Z","timestamp":1753891848105,"version":"3.41.2"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background and aim<\/jats:title><jats:p>Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are first-line antiviral treatment methods for chronic hepatitis B virus (HBV) infection. However, the different effects of TDF versus ETV on the prognosis of HBV-related hepatocellular carcinoma (HCC) after surgical resection remain controversial. We conducted this meta-analysis to assess the differences of TDF versus ETV in recurrence and survival for HBV-related HCC after liver resection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched MEDLINE, EMBASE, PubMed and Web of Science for the related studies published before January 2025. Meta-analysis was performed by use of a random-effects model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 15 studies were included in this meta-analysis. The pooled results showed that TDF was associated with better recurrence-free survival (RFS) (HR= 0.79, 95% CI 0.70-0.88) and lower risk of recurrence (HR=0.73, 95% CI 0.62-0.86) than ETV in HBV-related HCC patients after surgical resection. Further analysis indicated that TDF reduced the risk of late recurrence (HR= 0.70, 95% CI 0.55-0.88) rather than early recurrence (HR= 1.00, 95% CI 0.85-1.17) compared with ETV. Also, the pooled results revealed that TDF was associated with better overall survival (OS) (HR= 0.55, 95% CI 0.41-0.74) and lower risk of overall mortality (HR= 0.55, 95% CI 0.41-0.74) than ETV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This meta-analysis provided evidence that TDF has better benefits in improving survival and reducing late recurrence than ETV in HBV-related HCC patients after surgical resection.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1462794","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:24:50Z","timestamp":1748323490000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tenofovir disoproxil fumarate versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Yong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-fen","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-yan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.05.042","article-title":"Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance","volume":"73","author":"Mak","year":"2020","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7753","article-title":"Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005","volume":"27","author":"Altekruse","year":"2009","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/liv.2016.36.issue-2","article-title":"Positive HBcAb is associated with higher risk of early recurrence and poorer survival after curative resection of HBV-related HCC","volume":"36","author":"Li","year":"2016","journal-title":"Liver Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i14.2061","article-title":"Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV","volume":"11","author":"Ou","year":"2005","journal-title":"World J Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review","volume":"53","author":"Papatheodoridis","year":"2010","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-019-06640-8","article-title":"The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC","volume":"30","author":"Chen","year":"2020","journal-title":"Eur Radiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Electronic address eee, european association for the study of the l. EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JHC.S96085","article-title":"Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration","volume":"4","author":"Ma","year":"2017","journal-title":"J Hepatocell Carcinoma"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.06.003","article-title":"A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma","volume":"137","author":"Roayaie","year":"2009","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.07.009","article-title":"Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma","volume":"51","author":"Wu","year":"2009","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01872.x","article-title":"Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection","volume":"103","author":"Hung","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1478-3231.2007.01625.x","article-title":"Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection","volume":"28","author":"Kim","year":"2008","journal-title":"Liver Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.2018.25.issue-9","article-title":"The prognostic significance of serum HBeAg on the recurrence and long-term survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis","volume":"25","author":"Shen","year":"2018","journal-title":"J Viral Hepat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002727","article-title":"Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: A randomized controlled trial","volume":"268","author":"Huang","year":"2018","journal-title":"Ann Surg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/SLA.0000000000000858","article-title":"Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial","volume":"261","author":"Huang","year":"2015","journal-title":"Ann Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Electronic address eee, european association for the study of the l. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31289","article-title":"Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection","volume":"73","author":"Choi","year":"2021","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur","article-title":"Effect of tenofovir versus entecavir on the long-term prognosis in hepatocellular carcinoma patients with concurrent metabolic dysfunction-associated steatotic liver disease and hepatitis B","volume":"47","author":"Kong","year":"2024","journal-title":"Asian J Surg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejim.2021.02.019","article-title":"The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma","volume":"89","author":"Lee","year":"2021","journal-title":"Eur J Intern Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12885-024-12031-0","article-title":"Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma","volume":"24","author":"Liang","year":"2024","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17438","article-title":"Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy","volume":"57","author":"Kao","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v10.23","article-title":"Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study","volume":"10","author":"Qi","year":"2021","journal-title":"Cancer Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001864","article-title":"Nofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy","volume":"135","author":"Shen","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2020.11.019","article-title":"Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy","volume":"120","author":"Wu","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-018-0191-8","article-title":"Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection","volume":"13","author":"Zhang","year":"2018","journal-title":"Infect Agent Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000518940","article-title":"Tenofovir is superior to entecavir on tertiary prevention for BCLC stage 0\/A hepatocellular carcinoma after curative resection","volume":"11","author":"Tsai","year":"2022","journal-title":"Liver Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-022-01855-x","article-title":"Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection","volume":"57","author":"Wang","year":"2022","journal-title":"J Gastroenterol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000554","article-title":"Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial","volume":"109","author":"Linye","year":"2023","journal-title":"Int J Surg"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2022.07.003","article-title":"Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma","volume":"103","author":"Yun","year":"2022","journal-title":"Eur J Intern Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e2340353","DOI":"10.1001\/jamanetworkopen.2023.40353","article-title":"Tenofovir vs entecavir among patients with HBV-related HCC after resection","volume":"6","author":"Li","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2024.02.011","article-title":"Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy","volume":"123","author":"Chang","year":"2024","journal-title":"J Formos Med Assoc"},{"key":"B36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.cgh.2024.07.013","article-title":"Tenofovir is associated with a better prognosis than entecavir for hepatitis B virus-related hepatocellular carcinoma","volume":"23","author":"Chung","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/sim.v21:11","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jso.10284","article-title":"Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study","volume":"85","author":"Regimbeau","year":"2004","journal-title":"J Surg Oncol"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.12584","article-title":"Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis","volume":"46","author":"Liu","year":"2016","journal-title":"Hepatol Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2012.01602.x","article-title":"First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice","volume":"19","author":"Pol","year":"2012","journal-title":"J Viral Hepat"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.05.017","article-title":"Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB - is one NUC better than the other","volume":"71","author":"Wong","year":"2019","journal-title":"J Hepatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/hepr.12902","article-title":"Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients","volume":"48","author":"Koike","year":"2018","journal-title":"Hepatol Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection","volume":"67","author":"Murata","year":"2018","journal-title":"Gut"},{"key":"B44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.biopha.2017.01.077","article-title":"Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation","volume":"88","author":"Yan","year":"2017","journal-title":"BioMed Pharmacother"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.176.12.7686","article-title":"Antitumor activity of IFN-lambda in murine tumor models","volume":"176","author":"Sato","year":"2006","journal-title":"J Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0831-3","article-title":"Antitumor activity of type I and type III interferons in BNL hepatoma model","volume":"59","author":"Abushahba","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30956","article-title":"Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection","volume":"71","author":"Murata","year":"2020","journal-title":"Hepatology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1186\/s12885-021-08904-3","article-title":"Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database","volume":"21","author":"Ding","year":"2021","journal-title":"BMC Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00360-4","article-title":"Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy","volume":"38","author":"Imamura","year":"2003","journal-title":"J Hepatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001051","article-title":"Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir","volume":"30","author":"Tonon","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.035","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal","year":"2015","journal-title":"J Hepatol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1462794\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:24:52Z","timestamp":1748323492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1462794\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":52,"alternative-id":["10.3389\/fonc.2025.1462794"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1462794","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"article-number":"1462794"}}